International Conference on

In Vitro Diagnostics & In Vitro Fertilization

Theme: In Vitro Diagnostics: Current Trends, Future Advancements, Challenges & Opportunities

Event Date & Time

Event Location

London, UK

16 years of lifescience communication

Performers / Professionals From Around The Globe

Tracks & Key Topics

In Vitro Diagnostics- 2018

About In Vitro Diagnostics 2018

EuroScicon warmly welcomes experts around the globe to attend its much-awaited International Conference on In Vitro Diagnostics (In Vitro Diagnostics -2018), to be held on September 03-04, 2018, London, UK. This conference is based on the theme “In Vitro Diagnostics: Current trends, future challenges and opportunities”.

In Vitro Diagnostics Conference -2018 brings together the experts from both industry and academia associated with Invitro Diagnostics (IVD), Molecular Diagnostics, Companion Diagnostics, Point of Care Diagnostics/ Testing (POCT) and associated regulatory matters, R&D and Technology transfer etc.    

This In Vitro Diagnostics Congress comprises of Plenary sessions, Panel discussions, Round table discussions and Q&A Rounds, Oral presentations, Poster Presentations, Workshops/Symposiums, Young Researcher Forums to discuss the current trends, challenges, regulatory matters and future opportunities in the arena of Invitro Diagnostics Devices (IVD)

International Conference on In Vitro Diagnostics | Sep 03-04 | 2018 | London | UK | IVD Confereces | IVD Meetings | IVD Workshops | IVD Presentations | IVD instruments |US IVDs | CDx | VD Technology | diagnostics technologies | in vitro diagnostic research | in vitro diagnostic development | in vitro diagnostic manufacturers | point of care testing | in vitro diagnostics | clinical laboratory tests | assay system components | Medical Devices | Biomedical devices | Biomedical technologies | In vitro diagnostic multivariate index assay | Protein biomarkers | IVDMIA | IVD group | Who Global Model Regulatory Framework | Medical Devices | in Vitro Diagnostic Medical Devices | Who Medical Device | Immunochemistry Assay Development | Assay Development Service | Bioanalytical applications | Biomarkers | Biosensors | Blood gas analyser | Blood Glucose Meters | Blood Screening | Immunochemistry Assay Development | Assay Development Service | Bioanalytical applications | Biomarkers | Biosensors | Blood gas analyser | Blood Glucose Meters | Blood Screening | CE mark for IVD | Circulating tumor cell (CTC) | Clinical Evidence | Clinical Instruments | Clinical Microbiology | Compaliance | Companion Diagnostics | Custom Antibody | Data Management | Diagnosis | Diagnotics | Digital PCR | DNA testing | Enzyme Linked Immunosorbent Assay (ELISA) | Gene Diagnostics | Genetic Testing | Haematological diagnostics | Haemoglobin Meters | Hematological Diagnosis | Immuno assay | Immunoassay | Immunochemical labeling kits | In Vitro Diagnostics | In vitro diagnostics applications | In Vitro Diagnostics Devices | In vitro diagnostics Manufacturing | In vitro diagnostics technology | In Vitro diagnostics tests | Industry Classification | IVD Classifications | IVD Design | IVD devices | IVD Instruments | IVD Manufacturers | IVD Market Drivers | IVD Market Intelligence | IVD Market Landscape | IVD Market Reports | IVD Market Statistics | IVD Reagents | IVD Regulation | IVD Tests | IVDS | Lab | on | a | chip | Lateral flow assays | Liquid biopsy | Microarray technology | Microfluidics | Mobile healthcare | Molecular assays | Molecular Diagnostics | Nanomaterial | based assays | Next | generation sequencing (NGS) | Noninvasive prenatal testing (NIPT) | Oncology Diagnosis | Paper | based assays | Patient self | testing | PCR | POCT | Point of Care Diagnostics | Point | of | care | Post Market Surveillance | Precision Medicine | Primary antibodies | Q PCR | Quality Control | Quality system in IVD | Radioimmunoassay | Reagents | Regulatory affair | Secondary antibodies | Sepsis markers | Signal enhancement | Smartphone | based devices | Stroke markers | Surface plasmon resonance | UDI implementation | UL mark for IVD | Companion Diagnostics | Disease detection | Disease diagnosis | Disease prevention | DNA Microarrays | DNA testing | Electrochemistry | ELISA | Exosomes | Gene Expression | Genetic testing | Haematological diagnostics | Immuno assay | Immunoassays | In Vitro Diagnostics | In Vitro diagnostics tests | Infectious disease | IVD | Liquid biopsy | Micro Array | Molecular assays | Molecular assays | Molecular Diagnostics | NGS | PCR | POCT | Point of Care Diagnostics | RT PCR | Screening | IVD Product Manufacturers | Group Purchase Organizations (GPOs) | Original Equipment Manufacturers (OEM) | Pathologists and Pathology Laboratories | Distributors of IVD Products | Hospitals and Clinics | Healthcare Institutions | Research Institutes | Market Research and Consulting Firms | Reagents & Kits | Instruments | Services | Data Management Software | Clinical Chemistry | Basic Metabolic Panel | Electrolyte Panel | Liver Panel | Lipid Profile | Renal Profile | Thyroid Function Panel | Specialty Chemical Tests | Immunochemistry/Immunoassay | Enzyme-Linked Immunosorbent Assay (ELISA) | Chemiluminescence Immunoassay (CLIA) | Fluorescence Immunoassay (FIA) | Colorimetric Immunoassay (CI) | Radioimmunoassays (RIA) | Rapid Tests | Western Blot | ELISPOT | Hematology | Coagulation & Hemostasis | Clinical Microbiology | Molecular Diagnostics (MDx) | Polymerase Chain Reaction (PCR) | Isothermal Nucleic Acid Amplification Technology (INAAT) | Microarrays | Hybridization | DNA Sequencing & Next-generation Sequencing | Other MDx technologies | Other Technologies | Global In Vitro Diagnostics Market | by Application | Diabetes | Infectious Diseases | Oncology/Cancer | Cardiology | Nephrology | Autoimmune Diseases | Drug Testing | HIV/Aids | Other Applications | Global In Vitro Diagnostics Market | by End User | Hospitals | Laboratories | Academic Institutes | Point-Of-Care Testing | Patient Self-Testing | End Users | immunoassays | point of care | molecular diagnostics | hematology | coagulation | microbiology | clinical techniques | microbiology | nstruments | reagents | services | data management systems | diabetes | oncology | cardiology | HIV/AIDS | autoimmune disease | nephrology | drug testing | IVD market | clinical laboratory testing | near-patient testing | self-testing | Prognosis of prediabetes and diabetes | Prediction of gestational diabetes | Treatment selection and monitoring | Guide development of islet sparing | disease-modifying drugs | Companion diagnostics | Direct assessment of pancreatic islet health | Improved efficiency and convenience compared to oral glucose test | Measurements complementary to glycemia | Early diagnosis of pheochromocytomas and other NET in plasma. | Accurate prognostic assessment | in vitro diagnostics | immunoassays | lateral flow assays | nanomaterial-based assays | biomarkers | lab-on-a-chip | microfluidics | electrochemistry | biosensors | signal enhancement | surface plasmon resonance | microarrays | paper-based assays | smartphone-based devices | mobile healthcare | point-of-care | bioanalytical applications | Antigen | AP (Alkaline Phosphatase) | Array | Assay diluent | Assay sensitivity | BCIP | Blocking | Blotting | Chemiluminescent substrate | Clinical sensitivity | Clinical specificity | Colorimetric substrate | Conjugate | Cross-reactivity | Detection limit | Diagnostic assay | Dilution | Dynamic range | ELISA (Enzyme-Linked ImmunoSorbant Assay) | Enzyme | Heterophilic interference | HRP (Horseradish Peroxidase) | Immunoassay | Immunoblotting | Immunohistochemistry | In situ hybridization (ISH) | Interference | IVD (In Vitro Diagnostics) | Matrix effect | Membrane | Microwell | Molecular diagnostics | Multiplexing | Non-specific binding | Passivating surface chemistry | pNPP | Protein stabilizers | Rheumatoid factor | Sample matrix interference | Signal | Substrate | Test performance | TMB | Western Blot | ID/AST Test | Auto ID | AST Systems | Manual ID | AST Systems | Blood Culture | Chromogenic Media | Rapid Micro,ID/AST Leader Market | Infectious Disease Immunoassays | Lab-Based | POC | Home Testing | Laboratory Infectious Disease | Immunoassays Sales by Disease,Hepatitis | HIV | Mycology | Parasitology | Respiratory | Sepsis | STDs | ToRCH | Infectious Disease Diagnostic Sales– North America | Western Europe | Japan | China | India | Latin America | ROW | Blood Screening Test Market Size and Company Market Share | Worldwide Cancer Diagnostic Market | Global Cancer IVD Market | Clinical Laboratory Services | Marketing Screening Tests for Prostate Specific Antige | Regulatory Strategy Expertise | FDA Negotiation | Clinical Trial Protocol Development | Clinical Site Recruitment | Clinical Trial Management | Statistical Planning and Analysis | Final Clinical Trial Reports | Regulatory Submissions | Quality Manufacturing Audits | Broad Selection of Clinical Diagnostic Analyzers | Abbott IMX | Abbott AxSym Plus | Abbott Architect | | Roche ElecySys 2010 | Siemens/Dade RXL | Tosoh AIA-600-II | Complement of Molecular Diagnostic Techniques | Full suite of CLSI Testing required by FDA-OIVD | IVD Test Technology Evaluation & Optimization | IVD Test Development & Optimization | Association of Medical Diagnostic Manufacturers | American Association for Clinical Chemistry | U.S. Food and Drug Administration | Clinical and Laboratory Standards Institute | Cancer Markers & PGx | Histology (In situ hybridization | HPV) | Microbiology/Virology (HAI; HIV; Hepatitis; GC/Chlamydia; Respiratory;Organism ID; Mycobacteria | TB; Others) | Blood Screening | Coagulation & PGx | Prenatal Testing | Inherited Diseases Testing | Tissue Typing | Organ Transplant Testing (HLA Typing) | Circulating Tumor Cells (CTCs) | Clinical Sequencing | Flow Cytometry | Cancer IVD Market | Cancer Test Services Market | Sequencing in Cancer Testing | Tissue Function Tests | PSA | CEA and Other Immunoassays | Flow Cytometry | Pap and HPV Testing | FOB and Other Rapid Tests | Molecular Oncology Assays | Tissue Microarrays | Methylated DNA | In situ hybridization (ISH) | Immunohistochemistry (IHC) | Circulating Tumor Cells | Companion Testing and CDX Products | Chromosome Analysis (Karyotyping) | Cytology/Histology Stains | Tests for Fecal Occult Blood | Immunoassays | Overview - Immunoassays | Immunoassay Instrument Platforms | Immunohistochemistry (IHC) | Flow Cytometry | Fluorescence in situ Hybridization (FISH) and Chromogenic in situ Hybridization(CISH) | Nucleic Acid Amplification Technologies | Analysis of Gene Expression Patterns (Gene Signatures) | Microarrays | Protein Microarrays | DNA Microarrays | Chromosomal Microarrays | Tissue Microarrays | Sequencing Technologies | Sanger Sequencing | Early Next Generation Sequencing Technologies | Sequencing by Synthesis (SBS) | Supported Oligonucleotide Ligation and Detection (SOLiD) | Ion Torrent Sequencing | True Single Molecule Sequencing (tSMS) | Single Molecule Real Time (SMRT) Sequencing | DNA Nanoball Sequencing | Nanopore Sequencing | Other Sequencing Technologies | Mass Spectrometry | Mass Spectrometry Technology | Research and Clinical Applications of Mass Spectrometry | Circulating Tumor DNA (Cell Free DNA) | Circulating Tumor Cells (CTCs) | Cell-Based Assays (Live Cell Cancer Tests) | Digital Pathology and Image Cytometry | Information Technology | Assess Risk of Developing Cancer | Cancer Screening | Cancer Screening – Pap Smear and Human Papillomavirus (HPV) Testing | Colorectal Cancer Screening | Prostate Cancer Screening | Screening for Other Cancers | Diagnosis/Prognosis/Monitoring of Cancer | Personalized Medicine/Companion Diagnostics/Precision Testing | Drug Metabolism | Predicting Response to Therapy | FIVE: CANCER DIAGNOSTIC MARKETS | In Vitro Diagnostic Kits Marketed to Clinical Laboratories | Point-of-Care Tests for Cancer | Clinical Laboratory Test Services | Investments and Financing Agreements for Cancer Diagnostic Companies | Agreements with Other Companies | Acquisitions of Cancer Diagnostic Companies | Selected Other Agreements | Cancer Diagnostic Market Drivers | Advances in Technology Changing the Future of Cancer Diagnostics | Impact of Companion Diagnostic Tests | Limited Tissue from Biopsies for Growing Number of Cancer Tests | Laboratory Developed Tests and the FDA | Cost and Reimbursement Issues | Physician Education | Acceptance | and Use of New Cancer Tests | Competition | Future Prospects | In Vitro Cancer Diagnostics Market by Geographical Distribution | Clinical Laboratory Testing Market – Cancer Diagnostics | In Vitro Cancer Diagnostics Market Segments | Histology/Cytology | Immunoassays | Rapid Tests | Molecular (Nucleic Acid-Based) Assays | M Genomics Ltd. | 20/20 GeneSystems | Inc. | AB SCIEX | Abbott Laboratories | Abcodia Ltd. | Abingdon Health Ltd | Abnova Corporation | ACT Genomics Co. | Ltd. | Adaptive Biotechnologies Corporation | Admera Health (a GENEWIZ company) | Advanced Cell Diagnostics | Affymetrix | Inc. | Agena Bioscience Inc. | Agendia NV | Agilent Technologies Inc. | Alere Inc. | Ambry Genetics Corp. | Amoy Diagnostics Co. | Ltd. | ANGLE plc | ApoCell | Inc. | Applied Proteomics | Inc. | Applied Spectral Imaging | Inc. | Arbor Vita Corporation | ARKRAY | Inc. | ARUP Laboratories | Astra Biotech GmbH | Asuragen | Inc. | AsymmetRx Medical | Inc. | Atossa Genetics Inc. | AutoGenomics | Inc | Avant Diagnostics | Inc. (formerly Arrayit Diagnostics Inc.) | Axela | Inc | AXO Science | Beckman Coulter | Inc. (subsidiary of Danaher Corporation) | Becton | Dickinson and Company (BD) | BGI-Shenzhen | The Binding Site Group Ltd. | Biocare Medical | LLC | Biocartis SA | Biocept | Inc. | Biodesix | Inc. | BioFluidica | BioGenex | Biological Dynamics Inc. | BioMarker Strategies | bioMérieux SA | BioMosaics | Bio-Rad Laboratories | Inc. | Bio-Reference Laboratories | Inc. (BRLI) | BioSystems | bioTheranostics (a bioMérieux company) | Biotype Diagnostic GmbH | BioView Ltd | Boditech Med Inc. | Cancer Genetics | Inc. | Canopus Bioscience Ltd. | Caprion | Inc. | Caris Life Sciences | Castle Biosciences | Inc. | CDx Diagnostics | Celerus Diagnostics | Inc. | Cellmid Ltd. | Centogene AG | Cepheid | Cernostics | Cirdan Imaging Ltd | Clarient Diagnostic Services | Inc. (a GE Healthcare company) | Clearbridge BioMedics Pte Ltd | Color Genomics | Inc. | Counsyl | Inc. | Cube Dx GmbH | Cynvenio Biosystems | Inc. | CytoTest Inc. | Dako A/S (an Agilent company) | Danaher Corporation | DermTech | Inc. | DiaCarta | Inc. | DiaSorin S.p.A. | DiaTech Oncology | EDP Biotech Corporation | Eiken Chemical Co. | Ltd. | EntroGen | Inc. | Enzo Biochem | Inc | Enzo Life Sciences | Inc. | Enzo Clinical Labs | Inc. | Epic Sciences | Inc. | Epigenomics AG | Eutropics Pharmaceuticals | Exact Sciences Corporation | Exosome Diagnostics | Inc. | Fluxion Biosciences | Inc. | Foundation Medicine | Inc. | Fujirebio Inc. | Fujirebio Diagnositics | Inc. | GE Healthcare | Genalyte | Inc. | GeneCentric Diagnostics | Inc. | Genection | Inc. (an Invivoscribe company) | GeneDx | GeneNews Limited | Genetic Technologies Limited / Phenogen Sciences | Inc. (U.S. division) | GenomeDx Biosciences | Genomica S.A.U. | Genomic Health | Inc. | Genomic Vision | Genoptix (a Novartis company) | GenPath / GenPath Women’s Health and GenPath Oncology | Guardant Health | Inc. | HalioDx | Healgen Scientific LLC | Helomics Corporation | Hologic | Inc. | HTG Molecular Diagnostics | Inc. | Human Longevity | Inc. | Icellate AB | Ikonisys | Inc. | Illumina | Inc. | ImCare BioTech | Immunovia AB | IncellDx | Inc. | Inform Genomics | Inc. | Financings | Other Agreements | Inivata Ltd. | Innovations Exchange Pte Ltd (INEX) | Insight Genetics | Inc. | IntegraGen SA | Integrated Diagnostics | Inc. | Invitae Corporation | Invivoscribe Technologies | Inc. | Iris BioTechnologies Inc. | Janssen Diagnostics / Janssen Diagnostics BVBA | Janssen Diagnostics | LLC | Laboratory Corporation of America (LabCorp) / Integrated Genetics | Leica Biosystems Inc. (a Danaher company) | Leica Microsystems (a Danaher company) | Lifecode | Inc. | MagArray | Inc. | Martell Diagnostic Laboratories | Inc. | Matrix-Bio | Inc. | Mayo Medical Laboratories and Mayo Clinic | Medical & Biological Laboratories Co. | Ltd. (MBL) | MBL International Corporation | MDxHealth SA | Metamark Genetics | Inc. | MetaStat | Inc. | MolecularMD Corporation | Multiplicom NV | Myriad Genetics | Inc. | Myriad RBM | Inc. | NanoIVD | Inc. | NanoString Technologies | Inc. | NeoGenomics | Inc. / NeoGenomics Laboratories | NewGene Ltd. | New Oncology AG | Nuclea Biotechnologies | Inc. | Ohmx Corporation | Omnyx | Oncimmune Ltd. | Oncimmune (USA) LLC (acquired by HDL Inc.) | Health Diagnostic Laboratory | Inc. | OncoCyte Corporation | OncoDNA SA | OncoHealth Corp. | Oncolab | Inc. | Oncolys BioPharma Inc. | Oncompass GmbH | Onconome | Inc. | OncoPlex Diagnostics (OncoPlexDx) | Oncospire Genomics | OPKO Health | Inc. / OPKO Diagnostics | Orion Genomics | Ortho-Clinical Diagnostics | OvaGene Oncology Inc. | Oxford Cancer Biomarkers Ltd. | Oxford Gene Technology | Pacific Edge Limited | Pathway Genomics Corporation | Personal Genome Diagnostics | Inc. | PGXL Laboratories | Phenomenome Discoveries Inc. | Polymedco | Inc. | PreTect AS | PrognosDx Health | Inc. | Provista Diagnostics | Inc. | QIAGEN N.V. | QuanDx | Quanterix Corporation | QuantuMDx Group | Quest Diagnostics | RainDance Technologies | Inc. | Randox Laboratories Ltd | Rarecells SAS | Response Genetics | Inc. | Rheonix | Inc. | RiboMed Biotechnologies | Inc. | Roche | Rosetta Genomics Ltd. | ScheBo-Biotech AG | ScreenCell | Sequenom | Inc. | Siemens Healthcare Diagnostics | Symbiodx | Sysmex Corporation | TeloVISION | LLC | Theranostics Health Inc. | Thermo Fisher Scientific | Inc. | Tosoh Corporation | Tosoh Bioscience | Inc. | Transgenomic | Inc. | TrimGen Corporation | TrovaGene | Inc. | Vela Diagnostics | Ventana Medical Systems | Inc. (member of the Roche Group) | Veracyte | Inc. | Wako Diagnostics | Wako Pure Chemical Industries | Ltd. | | Abbott Diagnostics | IntelligentMDx Alliance | PLEX-ID | Iridica | Histology | Alere Inc. | Beckman Coulter | Inc. / Danaher | Lab Services | Sequencing | Genomics | Information Technology | Becton | Dickinson and Company (BD) | The BD MAX Enterprise | Oncology | HPV | Sequencing | Initiatives | Mass Spectrometry | Flow Spectrometry | Bio-Rad Laboratories | Inc. | Controls | Digital PCR | bioMérieux Inc | Expansion | Oncology | Molecular Strategy | Sequencing Service | Danaher Corporation | General Electric - GE Healthcare | Clarient Diagnostic Services | Inc. | Hologic | Inc. | Product News | The Gen-Probe Business | Panther System | Blood Bank | Quest Contract | QIAGEN N.V. | Personalized Healthcare | Infectious Disease Testing | Transplant Medicine and HAIs | HPV | Companion Diagnostics | Liquid Biopsy/CTC | Instrumentation Base | Rotor-Gene Q – Clinical Diagnostics | Sequencing | Exosomes | Information Technology | Collaborations | Forensics | Roche Diagnostics | New Enterprises | Global Access Program for HIV | Core Molecular Tests | STDs | A POC Enterprise – Liat | Prenatal and cfDNA | HPV | Blood Bank | Liquid Biopsy | Sequencing – Putting the Pieces Together | Siemens Healthcare Diagnostics | Histology | Molecular | Companion Diagnostics | Sequencing | China | Sysmex Corporation | Inostics GmbH | Intraoperative Test | Flow Cytometry | Thermo Fisher Scientific Inc. | Molecular Microbiology | Microbiology IT | Transplant | Quality Control | Mass Spectrometry | EIGHTEEN: COMPANY PROFILES: MAJOR MOLECULAR COMPANIES | Affymetrix Inc. | Agilent Technologies | Agilent in Genomics | PCR | Sequencing | Arrays | Sample Management | Mass Spectrometry | Expansion | Asuragen Inc. | Controls | Sample Collection | Sequencing | BGI | With Complete Genomics | BGI Projects | Cepheid | Hospital Acquired Infections (HAI) | TB | Infectious Diseases | Virology | Oncology | Eiken Chemical Co. | Ltd | Enzo Biochem Inc. | IP Situation | Illumina | Sequencing | Sequencing Kits | Sample Prep | IVD Business | Oncology | HLA Typing | IT | Forensics | CLIA Lab Service | Nanopore Sequencing | Sample to Insight | Making a Market | IP Situation | Life Technologies Corporation | Instrumentation and Applications | Liquid Biopsy | Sequencing | Life Technologies an IVD Company | Partnerships Worldwide | Life and Quidel Develop Diagnostics on the 7500 Fast Dx | Sepsis | HIV | Emerging Pathogens | Bacterial Typing | Personalized Medicine | Forensic | PerkinElmer | Inc. (PE) | Newborn Testing | Prenatal Testing | Sequencing | Mass Spectrometry | Information Technology | China | RainDance Technologies | Inc. | Market Expansion | NINETEEN: COMPANY PROFILES: PARTICIPANTS | AutoGenomics Inc. | Biocartis SA | Connectivity | Instrumentation | Collaborations | Idylla News | DiaSorin S.p.A | EKF Diagnostics Holdings Plc | ELITech Group | Epigenomics | Exosome Diagnostics | Inc. | Fluidigm Corporation | Fujirebio Diagnostics | Inc. | GenMark Diagnostics | Genome Diagnostics BV (GenDx) | Luminex Corporation | Business Expansion | MAGPIX Multiplexing | Next Generation NxTag | Product News | Menarini Diagnostics | Nanostring Technologies | Inc. | Alliances | LDTs | Pacific Biosciences of California | Inc. (PacBio) | Quidel Corporation | Lyra Product Line | Solana Molecular System | AmpliVue Product Line | Savanna (formerly Wildcat) | Acquisitions | Rubicon Genomics | Inc. | Transgenomic | Inc. | Alliances | Lab Services | Diagnostic Tools Division | TrovaGene | Inc. | WaferGen Bio-systems | Inc. | TWENTY: COMPANY PROFILES: GREAT EXPECTATIONS | Genomic Vision | GENOMICA S.A.U. | IncellDx | Inc. | Inivata | IntegenX Inc | Linkage Biosciences | Inc. | Savyon Diagnostics | Selventa | VolitionRx Limited | TWENTY-ONE: COMPANY PROFILES: NEWCOMERS | B Braun CeGaT | LLC | Canon BioMedical | Inc. | DestiNA Genomics Ltd | DiamiR | LLC | Randox Laboratories Ltd. | TWENTY-TWO: COMPANY PROFILES: TEST SERVICE PROVIDERS | 23andMe | What a Difference a Few Years Makes | The Move to Building a Research Company | Therapeutics Group | Ancestry | Outside the U.S. | Adaptive Biotechnologies Corporation | Agendia BV | AltheaDx Diagnostics | Inc. | Ambry Genetics | Oncology | Cardiac | Prenatal | Information Technology | ARUP Laboratories | Assurex Health | Athena Diagnostics | Bio-Reference Laboratories | Inc. (BRLI) | bioTheranostics | Cancer Genetics | Inc. (CGI) | The Response Genetics Acquisition | CareDx | Inc. | Caris Life Sciences | Centogene AG | Complete Genomics | Counsyl | Exact Sciences Corp. | Foundation Medicine Inc. | Genomic Health | Inc. | Market Uptake | Sequencing | Liquid Biopsy | Service Spin Off | Helomics Corporation | IntegraGen | Invitae Corporation | LabCorp | Laboratory Corporation of America | Infectious Diseases | Prenatal | Sequencing | Oncology | BRCA Saga | Information Technology | Forensic | Collaborations | Mayo Medical Laboratories | Information Technology | MDxHealth SA | Myriad Genetics | Product News | Companion Tests | Beyond Cancer | The U.S. Market | IP Update | Pathway Genomics Corporation | Quest Diagnostics | Oncology | Toxicology | Prenatal and Women’s Health | Market Expansion | Quest Partners for Market Accessibility | Rosetta Genomics Ltd. | Expansion | Veracyte | Inc. | TWENTY-THREE: COMPANY PROFILES: POINT OF CARE TEST SPECIALISTS | Atlas Genetics Ltd. | Biomeme | Inc. | DiAssess Inc | DNA Electronics Ltd (DNAe) | Enigma Diagnostics Limited | Entopsis | Epistem Holdings plc | InSilixa Inc. | Lucigen | PositiveID Corporation | QuantuMDx Group Limited | Rheonix | Inc. | Scanogen Inc. | Ubiquitome | Veredus Laboratories Pte Ltd | Xagenic

Why Attend In Vitro Diagnostics-2018

  • Meet the experts from 25+ countries around the globe
  • Earn up to 21 CME credits
  • Evaluate your research and share your ideas with global experts
  • World-class platform to Exhibit your products and services
  • Special workshop/ Symposium, B2B and interactive sessions, CME Meetings, with industry Sponsors and Exhibitors
  • More than 30 presentations from Industry and Academic leaders
  • One- on -one interaction with eminent scientists in the field of In Vitro Diagnostics (IVD)
  • Well organizing program with 5+ hours of networking sessions
  • Interactive panel discussions and Q&A sessions
  • Lively Exhibition area filled with the leading industry solution providers
  • Hear direct feedback and share experience and learn about the regulatory matters from the experts of FDA, BSI, UL, LRQA, TUV SUD, LNE/GMED and TUV Rheinland representatives

Who Should Attend

In Vitro Diagnostics Conference 2018 Rome, Italy provides an international platform for experts working in the field of Invitro Diagnostics (IVD), Companion diagnostics, Point of care diagnostics/ testing (POCT). In Vitro Diagnostics 2018 welcomes In Vitro Diagnostics Device (IVD) manufacturers (IVD), technology providers, vendors, suppliers, regulatory authorities and regulatory service providers, companies in the segments of IVD and PCOT, and Laboratory as well as academic experts in the areas of In Vitro Diagnostics, Point of Care Diagnostics and Companion Diagnostics.  

Professionals from Hospitals, Laboratories and Academics:

Directors, Deans, Research Professionals, Laboratory heads, Lab managers, Lab technicians, Medical/ Biomedical scientists, Professors, Associate Professors, Assistant Professors, Research Fellows working in the arena of In Vitro Diagnostics and its applied fields, but not limited to:  

Industry partners and professionals in the arena of :

Top USA In Vitro Diagnostics (IVD) Companies:

  • Danaher
  • Abbott Laboratories
  • Johnson & Johnson (J&J)
  • Bio-Rad
  • Becton Dickinson
  • Thermo Fisher Scientific
  • Beckman Coulter
  • Dade Behring

Top Europe In Vitro Diagnostics (IVD) Companies:

  • Roche
  • Bayer Diagnostics 
  • Siemens
  • BioMérieux
  • Alacris Theranostics 
  • ESE GmbH

Top Japan In Vitro Diagnostics (IVD) Companies:

  • Sysmex
  • Arkray
  • Olympus Corporation
  • Life Technologies

Top Global Emerging In Vitro Diagnostics (IVD) Companies

  • Dako (Agilent Technologies)
  • Genomic Health
  • Laboratory Corporation of America (LabCorp)
  • MDxHealth
  • Myriad Genetics
  • QIAGEN

Scientific Sessions

In Vitro Diagnostics (IVD) are the medical devices, accessories, instruments, reagents and systems deployed to perform medical test on samples (e.g., blood, urine and tissue taken from human body) to diagnose diseases, detects infections, diagnose medical conditions, monitor drug therapies, prevent diseases. Some tests usually performed in authorized laboratories by the trained healthcare professionals and some tests can be done at home.
 
Devices may range from simple tests to sophisticated DNA technology including calibrators, control materials, kits, reagents, software, or related instruments. IVD is an important segment in the global healthcare industry. The marketplace is witnessed rapid growth supported by advancements in technologies, evolvement of new tools, improvement in disease monitoring, higher demand of OTC tests, increased prevalence of infectious and other diseases like oncology, cardiovascular etc. IVD products are classified into Class I, III and III by FDA regulations to assure their safety and effectiveness.
 
Point-of-care testing (POCT) are the medical tests that are performed by trained healthcare professionals at or near the site of patient. Main POCTs include blood and urine tests. POCT is aimed to collect specimen and get accurate results in a very short span of time. POCTs are mainly used in primary care, secondary care and community care based settings. POCT are performed via portable instruments such as blood glucose meter, blood gas, pH, electrolyte, metabolite and haemoglobin measurement meters.
 
A Companion Diagnostic is a medical device/ diagnostic test/ imaging tool,  used companion to drugs, provides information regarding the applicability of drug or biologics to a specific person. It helps the healthcare professionals to determine whether the product will be beneficial to the patients or will have any risks or side effects.
 
Molecular Diagnostics is a collection of various techniques that are used to analyse biological markers in the proteome and genome and how their cells expressed the genes by the application of molecular biology to genetic testing. Globally the use of Molecular diagnostics growing rapidly. Major clinical applications are in the areas of oncology, Infectious disease, genetic diseases, pharmacogenomics,  human leukocyte antigen typing; and coagulation.  
 
Last five decades has seen a tremendous growth in immunodiagnostics tests and it emerged as a potential diagnostic technique.  The radioimmunoassay and Enzyme Linked Immunosorbent Assay (ELISA) were the predominant techniques during the initial era of immunodiagnostics.
 
Noninvasive prenatal testing (NIPT), Liquid biopsy, Next-generation sequencing (NGS), and circulating tumor cell (CTC) tests etc. are considered as the future of the In Vitro Diagnostics (IVD). These areas of the IVD market is expected to witness a rapid growth in coming few years. In coming five years, the cost of NGS test will rise from $250 million to $800 million with the total number of NGS sales only rise from 100 million to 300 million.
 
Though globally, the growth of IVD market is stagnant, it is predicted that NIPT will grow at a rate of 20% in USA and even more in abroad. Other future IVD devices include point of care biochemistry analyser (eg. Abbott i-STAT) blood gas analyser (eg. biosurfit spinit), immunology, haematology, and clinical chemistry analyser (eg. Acon Blood Glucose,  Total Cholesterol, Cholesterol 3-1,  Haemoglobin Meters and Hemoccult), and FOB test.
 
The US Food and Drug Administration (FDA) is involved in the regulation of IVDs or laboratory tests after the inception of the Medical Device Amendments of 1976. According to the guidelines of the FDA, IVD products are classified into Class I, II, or III which is based on the level of regulatory control that is essential to ensure the safety and effectiveness of devices.
 
The Code of Federal Regulations liststhe classification of existing IVDs in 21 CFR 862, 21 CFR 864, and 21 CFR 866. CLIA '88 is responsible for the quality standards of laboratory testing and an accreditation program for clinical laboratories. In the EU market, the In Vitro Diagnostics Directive (IVDD) 98/79/EC is the main regulatory requirements that medical device manufacturers comply with to get a CE marking in their products.
 
As one of the fastest-growing areas of In Vitro Diagnostics, Oncology testing to become an $8 billion market in 2018, an indepedent firm expects. It is not surprising that the most strenuous efforts in medical science are aimed at the number two killer disease. Oncology killed more than 7 million people worldwide in 2010, which is more than AIDS, masslaria, and tuberculosis combined. It is second heart leading disease-causing death across the globe. Oncology is a branch of medicine that works with the prevention, diagnosis, and treatment of cancer.
 
Infectious disease, also known as transmissible disease or communicable disease. Infections are caused by infectious agents including viruses, viroids, prions, bacteria, nematodes such as parasitic roundworms and pinworms, arthropods such as ticks, mites, fleas, and lice, fungi such as ringworm, and other microparasites such as tapeworms and other helminths. Infectious diseases are disorders that are caused by various organisms like bacteria, viruses, fungi or parasites.
 
They are transmitted through contaminated foods and through physical contacts. Infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), Herpes Simplex Virus (HSV), tuberculosis, measles, dengue, Chagas, cholera, and malaria are increasing across the globe, mostly in developing countries.
 
In Vitro Diagnostics (IVDs) help in identifying the pathogenic agent such as bacteria, viruses or fungi that are responsible  infectious diseases and alo helps to select the appropriate treatment options. Molecular Diagnostics Tests also helps to perform both targeted and syndromic Clinical Tests for Infectious Diseases resulting the incresing demands.
 
An IVD Medical Device defined as a device which, whether used alone or in combination for the in-vitro examination of specimens derived from the human body solely or principally to give information for diagnostic, monitoring or compatibility purposes. Biomarkers can be a substance used for examining organ function and condition.
 
There are two major types of Biomarkers: biomarkers of exposure, that are used in risk prediction, and biomarkers of disease, that are used in screening, diagnosis and monitoring of disease progression. Biomarkers are used for personalized medicine are typically categorized as either prognostic or predictive.
 
Cardiovascular ailment (CVD) is a class of infections that include the heart or veins. Cardiovascular sickness incorporates coronary corridor infections (CAD, for example, angina and myocardial dead tissue (usually known as a heart assault). Different CVDs incorporate stroke, heart disappointment, hypertensive coronary illness, rheumatic coronary illness, cardiomyopathy, heart arrhythmia, inherent coronary illness, valvular coronary illness, caritas, aortic aneurysms, fringe corridor sickness, thromboembolic infection, and venous thrombosis.
 
Diabetes, is likewise knows as diabetes mellitus, is a gathering of metabolic issue where high glucose levels over a drawn-out period found. Side effects of high glucose incorporate regular pee, expanded thirst, and expanded appetite. They are two sorts of diabetes: Type1DM, comes about because of insulin inadequacy, and Type2DM, comes about because of insulin protection and gestational diabetes that outcomes from pregnant ladies with medicinal history of diabetes. Prevention and treatment involve maintaining a healthy diet, regular physical exercise, a normal body weight, and avoiding tobacco use.
 
Traditional biosensors like glucose meters and glycohemoglobin test kits are commonly used for In Vitro Diagnosis of the disease and long-term management of diabetes. The increasing prevalence of diabetes and the demand for the diagnostic tests helps to drive the market and to go for new R&D in this sector to develop innovative products.Other Point of Care Tests such as HbA1c are preferred due to their capability of Rapid Diagnosis and management of diabetes with a reduced cost.
 
An Immunoassay is a biochemical test that measures the nearness or convergence of a macromolecule or a little particle in a solution using a counter acting agent (for the most part) or an antigen (some of the time). The particle identified by the Immunoassay is frequently alluded to as an "analyte" and is much of the time a protein, although it might be different sorts of atoms, of various size and sorts, if the best possible antibodies that have the sufficient properties for the test are created.
 
Analytes in organic fluids, for example, serum or pee are oftentimes measured utilizing Immunoassays for restorative and research purposes.  Some Immunoassays are simply carried out by mixing the reagents and sample and making a physical measurement. This kind of Assays are called homogenous Immunoassays or less frequently non-separation Immunoassays.
 
Nephrology is a claim to fame of pharmaceutical and paediatrics that frets about the kidneys: the investigation of ordinary kidney capacity and kidney issues, the conservation of kidney wellbeing, and the treatment of kidney issues, from eating routine and medicine to renal substitution treatment (dialysis and kidney transplantation).
 
Fundamental conditions that influence the kidneys, (for example, diabetes and immune system malady) and foundational issues that happen in view of kidney issues, (for example, renal osteodystrophy and hypertension) are additionally examined in nephrology. A doctor who has attempted extra preparing to wind up plainly a specialist in nephrology may call themselves a nephrologist or renal doctor.
 
History and physical examination are diagnostic workup in Nephrology. This may include inquiries regarding family history, general medical history, diet, medication use, drug use and occupation. Examination typically includes an assessment of volume state, blood pressure, skin, joints, abdomen and flank.

IVD Market Overview

In Vito Diagnostics Devices (IVD) Market: 

The In Vitro Diagnostics Devices (IVDs) are one of the major segment in the healthcare industry globally. The IVD market place witnessed a rapid growth propelled by the better and newer diagnostic tools, evolvement of new technologies, improved disease monitoring, and readily available with increased demand of Point of Care Diagnostic Tests (POCTs), increased ageing population, rising of chronic, infectious and other lifestyle related diseases, and increasing healthcare expenditure. Moreover, the IVDs have added a significant value to the overall disease diagnosis, treatment process and healthcare industry. The IVD segment is also positively supported by the funding agencies like NIH, NHR, NHS Trust, WHO etc to offer novel diagnostic modalities. Uncertainty in the regulatory landscape remained a big challenge in the IVD industry. In our In European Vitro Diagnostics-2018 Conference, the experts will discuss thoroughly regarding these issues and will pave a way, how to comply with these regulatory issues to ensure the fulfilling of growing market demands of IVDS, PCOTs and Companion Diagnostics.  

The global In Vitro Diagnostics (IVD) industry is under pressure because of incorporation of multi-disciplinary capabilities in chemistry, biology, and computational power that companies can leverage to develop new solutions to diagnose, treat and manage chronic diseases like cancer, diabetes and other cardiovascular diseases. There is a huge pressure on companies to build new competencies in product development, manufacturing and distribution of new technology platforms such as point-of-care molecular diagnostics and capture new growth opportunities in the precision medicine market. With the increased demand of IVDs, the re imbursement strategy is now a big challenge for the IVD companies in the western world. The rapid adaptation of Next Generation Sequencing (NGS) platforms, Liquid biopsies, Companion Diagnostics applications will rapidly drive the market in future.

As per a report the global revenues of IVD market will grow from $62bn in 2016 to $123bn by 2027 with a CAGR of 6.4% during the forecasted period. The major segments fuelling the growth include, Point of Care (POC) tests, Clinical Chemistry, Immunochemistry, Haematological Diagnostics, Microbiological applications and Genetic Testing.

The US, Japan and China remained were remained the top three markets of In Vitro Diagnostics in 2015 and will retain the same place till 2026, while India will be the fastest growing market during the same period and will be very close to China. 

Invitro Diagnostics Conference 2018

The European IVD market was worth $12.51Bn in 2015 and is expected to hit about $15.5Bn by 2024. This increase in market is attributed to the increased demand of promising and novel diagnostics technologies, increased numbers of geriatric population and increasing awareness among the population regarding the early diagnosis of life threatening diseases.In Europe, individuals aged 65 and above are expected to rise in number from 18.5% in 2014 to 28.7% of the total population, by the year 2080.

In Vitro Diagnosis Conference Europe 2018

The Molecular Diagnosis market contributes a major share in the IVD space. Among all the countries, USA captured the major market in Molecular Diagnosis (43%), followed by Europe (24.8%), China (9.3%), and Japan (6.9%).

in vitro diagnostics conference europe 2018

 

As per a report of European Diagnostic Manufacturers Association (EDMA), The revenues from IVD market in Europe (four largest European market) remained stagnant during 2007 to 2015 except Germany. In 2015, revenues increase 0.5% to reach €10,543M which was below the revenues of 2009 (€10,685). Though, the overall IVD revenues in Germany remained stagnated, modest growth observed in Germany (+1%). The growth has been observed in microbiology +2.2% and immunochemistry +2,5%. During the same period, the UK experienced the negative growth of -2.9% due to reduction in the cost of reagents mainly in Clinical Chemistry rapid test and POC. In Italy, market dropped with -1.3% compared to 2014. France IVD market remained stagnant with a small growth of +0.1%. Continuous economic crisis in Greece and Spain resulted a negative growth of -6,1% and -1,6% respectively. On the contrary, Portugal, though suffered economic chaos, showed positive +4,4 growth in IVD expenditure.

in vito diagnosis congress europe 2018

In Europe, an average of 10% of gross domestic product (GDP) is spent on healthcare. Among which around 7.3% is attributed to medical technologies, which is > 1% of GDP. The spending on medical technology is estimated to vary significantly across European countries,ranging from around 5% to 10% of the total healthcare expenditure9. Expenditure on medical technology per capita in Europe is at around €197.

in vitro diagnosis conference congress meeting europe 2018

The European Medical technology market is estimated is estimated to be €110Bn in 2015. As per the manufacturer prices, the European medical technology market is estimated to be contributed 28% of the global market. It placed second with 40% share the USA is placed number one. Among all European countries, Germany stood top (21%) in terms of share of the IVD market, followed by Italy 16%, France 13%, Spain 9% and the UK 8% and rest of the Europe 33%. 

In vitro diagnostics companion diagnostics IVD congress conferences 2018 Europe

As predicated by Evaluate, on a worldwide perspective, the in vitro diagnostics market is the largest sector, followed by cardiology and diagnostic imaging.  Among all the sector, in vitro diagnostics market is expected to grow highest till 2022 in terms of worldwide sales.

In vitro ivd diagnosis conference europe 2018

Learn More

Global Key Players in In Vitro Diagnostics

Top InVitro Diagnostics (IVD) Manufacturers

Distributors of In Vitro Diagnostic Products in UK and Europe

Distributors of IVD Products in the USA, Canada and North America

Distributors of In Vitro Diagnostic Products (IVD) in the Asia Pacific & ROW

Top In Vitro Diagnostics or Medical Devices Societies/ Associations/ Alliances Globally

Top USA/ Canada/North America Universities with IVD Research

Media Partners/Collaborator/Sponsors

A huge thanks to all our amazing partners. We couldn’t have a conference without you!

Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker